CRSP - CRISPR Therapeutics AG

These Are The Upcoming Catalysts For Crispr Therapeutics Stock

Crispr Therapeutics AG remains a Buy, supported by a robust pipeline, prudent capital management, and deep Vertex partnership despite slow Casgevy adoption. Casgevy's market penetration is limited by harsh preconditioning, but in vivo approaches and gentler regimens could unlock a vastly larger TAM in coming years. CRSP's diversified pipeline—spanning cardiovascular, diabetes, and CAR-T—offers multiple shots on goal, with key clinical readouts expected throughout 2026.

May 21, 2026 01:40 PM • seekingalpha.com

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

May 19, 2026 06:01 AM • zacks.com

The Best Stocks to Invest $3,000 In Right Now

Not every high-potential name costs a fortune to step into.

May 19, 2026 05:45 AM • fool.com

CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms

CRISPR Therapeutics NASDAQ: CRSP Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months.

May 15, 2026 04:14 PM • marketbeat.com

CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript

CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 12, 2026 03:50 PM • seekingalpha.com

1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?

The biotech's innovative platform could pay off.

May 11, 2026 12:15 PM • fool.com

VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings

Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.

May 08, 2026 10:21 AM • zacks.com

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

May 08, 2026 06:01 AM • zacks.com

Crispr Therapeutics Q1 Earnings: Casgevy Growth, H2 In-Vivo Catalysts Make Buy Case

Crispr Therapeutics AG is positioned as a long-term buy-and-hold, underpinned by its pioneering gene editing platform and commercial-stage asset Casgevy. Casgevy revenues fell sequentially, but >500 patients have initiated treatment, supporting a multibillion-dollar opportunity with a large, underpenetrated addressable market. CRSP's pipeline offers near-term catalysts in autoimmune and in-vivo gene editing, with several Phase 1 updates expected later this year.

May 06, 2026 05:12 AM • seekingalpha.com

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 1:40 p.m. PDT.

May 06, 2026 04:30 AM • globenewswire.com

CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates

CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.

May 05, 2026 05:21 AM • zacks.com

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.58 per share a year ago.

May 04, 2026 04:30 PM • zacks.com

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026.

May 04, 2026 12:30 PM • globenewswire.com

What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.

The biotech's candidate may treat a great number of illnesses that have one thing in common.

Apr 30, 2026 01:10 AM • fool.com

3 Growth Stocks That Could Generate 10X Returns

These stocks come with risk, but they also have some exciting long-term growth opportunities.

Apr 29, 2026 07:00 AM • fool.com

GSK (GSK) Tops Q1 Earnings and Revenue Estimates

GSK (GSK) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.13 per share a year ago.

Apr 29, 2026 04:10 AM • zacks.com

Why the Market Dipped But CRISPR Therapeutics AG (CRSP) Gained Today

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $52.06, representing a +2.1% change from its previous close.

Apr 28, 2026 03:01 PM • zacks.com

Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect

VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.

Apr 28, 2026 09:36 AM • zacks.com

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apr 28, 2026 07:09 AM • zacks.com

CRISPR Therapeutics to Report Q1 Earnings: Is a Beat in the Cards?

CRSP eyes a Q1 beat as rising Casgevy uptake, improving sales outlook and a strong Earnings ESP set the stage ahead of results.

Apr 27, 2026 05:06 AM • zacks.com

Crispr Therapeutics price target raised to $56 from $50 at Bernstein

$56.00 (was $52.83)

Bernstein

May 13, 2026 06:28 AM • TheFly

Crispr Therapeutics price target raised to $76 from $74 at Evercore ISI

$76.00 (was $55.56)

Evercore ISI

May 11, 2026 08:04 AM • TheFly

Crispr Therapeutics price target raised to $33 from $32 at Morgan Stanley

$33.00 (was $52.25)

Morgan Stanley

Feb 17, 2026 08:33 AM • TheFly

Crispr Therapeutics price target raised to $76 from $74 at Chardan

$76.00 (was $53.07)

Geulah Livshits · Chardan Capital

Feb 14, 2026 06:41 AM • TheFly

Crispr Therapeutics price target raised to $82 from $80 at Needham

$82.00 (was $53.89)

Needham

Feb 13, 2026 09:04 AM • TheFly

Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI

$74.00 (was $53.80)

Evercore ISI

Feb 13, 2026 09:02 AM • TheFly

Crispr Therapeutics price target lowered to $74 from $82 at Chardan

$74.00 (was $52.79)

Chardan Capital

Nov 26, 2025 05:12 AM • TheFly

CRISPR Therapeutics (CRSP) PT Raised to $50 at RBC Capital

$50.00 (was $54.58)

Luca Issi · RBC Capital

Nov 11, 2025 04:24 AM • StreetInsider

Crispr Therapeutics price target raised to $75 from $65 at Wells Fargo

$75.00 (was $73.09)

Yanan Zhu · Wells Fargo

Oct 13, 2025 07:33 AM • TheFly

Crispr Therapeutics initiated with a Buy at H.C. Wainwright

$65.00 (was $40.00)

Mitchell Kapoor · H.C. Wainwright

Feb 03, 2025 06:11 AM • TheFly

Oppenheimer Reiterates Outperform Rating on CRISPR Therapeutics (CRSP)

$95.00 (was $49.51)

Jay Olson · Oppenheimer

Nov 06, 2024 06:15 AM • StreetInsider

CRISPR Therapeutics (CRSP) PT Lowered to $67 at Leerink Partners

$67.00 (was $50.36)

Rick Bienkowski · Leerink Partners

Nov 05, 2024 03:25 PM • StreetInsider

Crispr Therapeutics price target lowered to $100 from $120 at Truist

$100.00 (was $46.55)

Joon Lee · Truist Financial

Aug 12, 2024 05:50 AM • TheFly

CRISPR Therapeutics (CRSP) PT Lowered to $84 at Needham

$84.00 (was $50.11)

Gil Blum · Needham

Aug 06, 2024 03:16 AM • StreetInsider

CRISPR Therapeutics (CRSP) PT Lowered to $59 at Stifel

$59.00 (was $50.01)

Benjamin Burnett · Stifel Nicolaus

Aug 06, 2024 02:54 AM • StreetInsider

CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital

$60.00 (was $50.13)

Luca Issi · RBC Capital

Aug 06, 2024 02:43 AM • StreetInsider

CRISPR Therapeutics (CRSP) PT Raised to $52 at Baird

$52.00 (was $53.29)

Jack Allen · Robert W. Baird

May 09, 2024 02:22 AM • StreetInsider

Citigroup Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $63

$63.00 (was $55.72)

Citigroup

Nov 23, 2022 04:01 AM • Benzinga

NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday

$79.30 (was $81.39)

Geulah Livshits · Chardan Capital

Aug 09, 2022 02:44 AM • Benzinga

3 Reason Why This Analyst Says CRISPR Therapeutics Is A Biotech Winner

$98.00 (was $70.73)

Kostas Biliouris · BMO Capital

Jun 17, 2022 07:04 AM • Benzinga